Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Cardiology

Expert Opinion / Conference Coverage · November 19, 2013

TCT: Practice Implications of Key New Data for the Interventional Cardiologist

 

Additional Info

  1. Steg PG, van ‘t Hof A, Hamm CW, et al, for the EUROMAX Investigators. Bivalirudin started during emergency transport for primary PCI. N Engl J Med. 2013;October 30; DOI: 10.1056/NEJM1311096.

  2. Bhatt DL. Intensifying platelet inhibition—navigating between Scylla and Charybdis. N Engl J Med. 2007;357:2078-2081.

  3. Bhatt DL, Stone GW, Mahaffrey KW, et al, for the CHAMPION PHOENIX Investigators. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med. 2013;368:1303-1313.

  4. Leon MB, Smith CR, Mack M, et al, for the PARTNER Trial Investigators. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med. 2010;363:1597-1607.

Disclosure statements are available on the authors' profiles:

Further Reading